B
Bull
Bull · 25%THTX
$3.26
シナリオ価格
$3.390
0.000 (0.00%)終値時点
Loading chart…
- High
- 3.400
- Open
- 3.360
- VWAP
- 3.38
- Vol
- 3.27M
- Mkt Cap
- 63.91M
- Low
- 3.340
- Amount
- 11.05M
- EV/EBITDA, TTM
- 5.08
Theratechnologies Inc. is a Canada-based specialty biopharmaceutical company focused on the commercialization of innovative therapies. The Company offers prescription products for individuals with human immunodeficient virus (HIV) in the United States and its pipeline is focused on specialized therapies designed to address unmet medical needs in both HIV and oncology. It markets two HIV products, namely EGRIFTA SV and Trogarzo; and has research programs in HIV and oncology. EGRIFTA SV is the therapy for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Trogarzo injection is used with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 who are failing their current regimen. Its pipeline includes Donidalorsen and Olezarsen, and the SORT1+ oncology platform. The Company is also focusing on tesamorelin life-cycle management in lipodystrophy.
バリュエーション指標
The current forward P/E ratio for Theratechnologies Inc (THTX) is 22.64, compared to its 5-year average forward P/E of 15.75.
Alphio AI Price Scenarios for THTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
イベントタイムライン
ニュース
8.509-16NewsfilterTheratechnologies Secures Final Court Approval for Acquisition by Future Pak Through Proposed Plan of Arrangement
- 8.509-12Newsfilter
Theratechnologies Shareholders Greenlight Acquisition Plan by Future Pak
5.009-05NASDAQ.COMTheratechnologies: EGRIFTA WR Now Accessible for HIV Patients with Excess Abdominal Fat
8.508-19GlobenewswireBRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving TEGNA Inc. (NYSE - TGNA), NorthWestern Energy Group, Inc. (Nasdaq - NWE), Theratechnologies Inc. (Nasdaq - THTX), and Dogwood State Bank (OTC - DSBX)
- 8.508-18Newsfilter
Theratechnologies Files Special Meeting Materials and Receives Interim Order for Acquisition by CB Biotechnology, a Future Pak Affiliate
THTX FAQ — answered by Alphio AI
Theratechnologies Inc. is a Canada-based specialty biopharmaceutical company focused on the commercialization of innovative therapies. The Company offers prescription products for individuals with human immunodeficient virus (HIV) in the United States and its pipeline is focused on specialized therapies designed to address unmet medical needs in both HIV and oncology. It markets two HIV products, namely EGRIFTA SV and Trogarzo; and has research programs in HIV and oncology. EGRIFTA SV is the therapy for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Trogarzo injection is used with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 who are failing their current regimen. Its pipeline includes Donidalorsen and Olezarsen, and the SORT1+ oncology platform. The Company is also focusing on tesamorelin life-cycle management in lipodystrophy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。